Inhalation CDMO sales will expand through 2036, with formulation development at 43.0% of service sales, commercial scale operations at 70.2% within the rising outsourcing of large-scale segment and commercial operations at 70.2% of the scale of operation category in 2026. The market was valued at USD 9.13 billion in 2025.